Ilumya Insurance Denied? How to Appeal Your Tildrakizumab Denial

Ilumya (tildrakizumab) is an FDA-approved IL-23 inhibitor for moderate-to-severe plaque psoriasis in adults. It targets the p19 subunit of IL-23, selectively blocking a key driver of the psoriatic inflammatory cascade while leaving other immune pathways intact. Despite strong clinical evidence and a favorable safety profile, insurance companies frequently deny Ilumya, often requiring patients to try other biologics first. Here's how to file a successful appeal.

What Ilumya Treats and Why Patients Need It

Ilumya specifically inhibits IL-23, a cytokine that drives the differentiation and activation of Th17 cells — the primary immune cells responsible for the skin inflammation in plaque psoriasis. By targeting IL-23 selectively, tildrakizumab disrupts the psoriatic cycle with high specificity.

In Phase 3 clinical trials (reSURFACE 1 and 2), Ilumya demonstrated:

• 66% of patients achieving PASI 90 at week 28 (90% reduction in psoriasis severity)
• Sustained responses with quarterly maintenance dosing after initial treatment
• Favorable safety profile with low infection risk

For patients with moderate-to-severe plaque psoriasis who have failed topical therapies or conventional systemic agents, biologic therapy is the standard of care per AAD (American Academy of Dermatology) guidelines. Ilumya, as an IL-23 inhibitor, offers highly targeted therapy that achieves skin clearance in the majority of patients.

Common Denial Reasons for Ilumya

Step therapy requirements: Plans typically require failure of topical corticosteroids, topical vitamin D analogs, phototherapy, and often at least one systemic therapy (methotrexate, cyclosporine, or acitretin) before approving a biologic. Some plans also require a trial of a TNF inhibitor (Humira, Enbrel) before approving an IL-23 inhibitor.

Severity threshold not documented: Most plans require documented BSA (body surface area) above a threshold (typically ≥10%) or PASI score ≥10 or ≥12, or involvement of special body areas (face, hands, feet, genitalia, nails) with lower BSA.

Preferred IL-23 or IL-17 biologic required first: Plans may prefer Skyrizi (risankizumab), Tremfya (guselkumab), or Taltz (ixekizumab) over Ilumya based on formulary contracts.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization missing or incomplete: Missing BSA/PASI documentation, incomplete prior treatment history, or missing specialist attestation.

Step-by-Step: How to Appeal an Ilumya Denial

Step 1: Identify the specific denial reason. Step therapy, severity threshold, preferred alternative?

Step 2: Document disease severity objectively. BSA percentage, PASI score, and DLQI (Dermatology Life Quality Index) should be in your medical record and appeal submission.

Step 3: Document your complete psoriasis treatment history. Topical corticosteroids (class and potency), topical calcineurin inhibitors, vitamin D analogs, phototherapy sessions, and any systemic therapies — with dates, durations, and response data.

Step 4: Have your dermatologist write a Letter of Medical Necessity documenting disease severity, treatment history, and clinical rationale for Ilumya.

Step 5: Address step therapy completion. If you've met the step therapy requirements, document each completed step clearly. If a required step is contraindicated, explain why.

Step 6: Submit the internal appeal and request peer-to-peer review.

Step 7: File an external appeal if needed.

What to Include in Your Ilumya Appeal Letter

• Policy/member information and claim reference
• Tildrakizumab (Ilumya) prescribed dose and indication
• Current PASI score, BSA percentage affected, and DLQI score
• Special body area involvement if applicable (face, hands, nails, genitalia)
• Complete prior psoriasis treatment history
• Prior systemic or biologic therapy history with outcomes
• Letter of Medical Necessity from dermatologist
• reSURFACE trial citations
• AAD psoriasis treatment guideline citations supporting biologic therapy
• Request for peer-to-peer review

Success Tips for Ilumya Appeals

Document special body area involvement. Even with BSA below the usual threshold, involvement of hands, feet, face, genitalia, or scalp can qualify a patient for biologic therapy because these areas cause disproportionate functional impairment. Insurers recognize special site criteria — use them.

Use the DLQI. A DLQI score above 10 indicates a very large impact on quality of life. If your psoriasis significantly affects your work, relationships, and daily activities, a high DLQI score makes the medical necessity argument powerfully.

Show phototherapy failure if required. If your plan requires phototherapy, document the number of sessions attempted, clinical response, and any practical barriers (travel, scheduling, phototoxicity, lack of access).

Quarterly dosing is an advantage. After the loading phase, Ilumya is dosed every 12 weeks — one of the least frequent dosing schedules among psoriasis biologics. This is a compliance and quality-of-life advantage worth noting in your appeal.

Include comorbid psoriatic arthritis if present. Psoriatic arthritis is a separate indication supported by some IL-23 inhibitors. If joint disease is also present, this strengthens the overall medical case.

Fight Back With ClaimBack

Plaque psoriasis can be physically and psychologically devastating. ClaimBack helps you fight insurance denials with clear, evidence-based appeals so you can access the biologic therapy your dermatologist prescribed.

Start your Ilumya appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied